SNSE
SNSE
NASDAQ · Biotechnology

Sensei Biotherapeutics Inc

$27.68
+0.80 (+2.98%)
Financial Highlights (FY 2025)
Revenue
6.00M
Net Income
-817,172
Gross Margin
61.1%
Profit Margin
-13.6%
Rev Growth
+2.3%
D/E Ratio
0.18
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 61.1% 61.1% 61.1%
Operating Margin -14.5% -13.7% -12.8%
Profit Margin -13.6% -12.0% -13.8%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 6.00M 5.90M 5.57M
Gross Profit 3.67M 3.61M 3.40M
Operating Income -867,126 -811,164 -710,675
Net Income -817,172 -706,875 -767,435
Gross Margin 61.1% 61.1% 61.1%
Operating Margin -14.5% -13.7% -12.8%
Profit Margin -13.6% -12.0% -13.8%
Rev Growth +2.3% +18.9% +16.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 1.60M 1.40M 1.77M
Total Equity 8.78M 8.51M 8.18M
D/E Ratio 0.18 0.16 0.22
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -1,135,758 -954,399 -978,652
Free Cash Flow -597,971 -436,320 -559,358